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Rationale: Previously, we demonstrated that intranasal infection of
BALB/c mice with respiratory syncytial virus (RSV) resulted in an
early 40% reduction in alveolar fluid clearance (AFC), an effect
mediated via P2Y purinergic receptors.
Objectives: To confirm that RSV-induced inhibition of AFC is medi-
ated by uridine triphosphate (UTP), and to demonstrate that inhibi-
tion of de novo pyrimidine synthesis with leflunomide prevents in-
creased UTP release after RSV infection, and thereby also prevents
inhibition of AFC by RSV.
Methods: BALB/c mice were infected intranasally with RSV strain A2.
AFC was measured in anesthetized, ventilated mice by instillation of
5% bovine serum albumin into the dependent lung. Some mice
were pretreated with leflunomide or 6-mercaptopurine.
Measurements and Main Results: RSV-mediated inhibition of AFC is
associated temporally with a 20-nM increase in UTP and ATP content
of bronchoalveolar lavage fluid, hypoxemia, and altered nasal po-
tential difference. RSV-mediated nucleotide release, AFC inhibition,
and physiologic sequelae thereof can be prevented by pretreatment
of mice with the de novo pyrimidine synthesis inhibitor leflunomide,
which is not toxic to the mice, and which does not affect RSV
replication in the lungs. In contrast, pretreatment of mice with
6-mercaptopurine, an inhibitor of de novo purine synthesis, has no
beneficial effect on AFC or other indicators of disease progression.
Finally, RSV-mediated inhibition of AFC is prevented by volume-
regulated anion channel inhibitors.
Conclusion: Pyrimidine synthesis or release pathways may provide
novel therapeutic targets to counter the pathophysiologic sequelae
of impaired AFC in RSV disease.
Keywords: ion transport; paramyxovirus infections; pneumonia, viral;
pulmonary edema
The dominant ion transport process of the alveolar epithelium
is active movement of Na ions from the airspace lining fluid
to the interstitium (1). This creates an osmotic gradient, causing
water to follow passively. This process of alveolar fluid clearance
(AFC) is crucial to efficient gas exchange. Importantly, patients
with acute lung injury with intact AFC have lower morbidity
and mortality than those with compromised AFC (2).
Respiratory syncytial virus (RSV) is the most common cause
of lower respiratory tract disease in infants and children world-
wide (3), but its pathogenesis remains poorly understood. Pre-
viously, we demonstrated that infection of BALB/c mice with
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RSV results in reduced AFC at early time points after infection,
and inferred that RSV-mediated inhibition of AFC 2 d after
infection was mediated by uridine triphosphate (UTP), acting
on P2Y receptors (P2YRs) on lung epithelial cells (4). The aim
of the current study was to confirm the central role of UTP
in mediating the inhibitory effects of RSV on AFC, and to
demonstrate that pharmacologic inhibition of de novo pyrimi-
dine synthesis with leflunomide prevents increased UTP release
after RSV infection, and thereby also prevents inhibition of AFC
by RSV. Furthermore, we demonstrated that blockage of RSV-
mediated AFC inhibition with leflunomide would improve pul-
monary edema and hypoxemia in RSV-infected mice. In addition,
because RSV may infect epithelial cells throughout the entire
respiratory tract, we determined whether RSV infection also alters
upper respiratory tract epithelial ion transport, and to determine
whether leflunomide treatment reverses any such effects. Finally,
we demonstrated that UTP release into the alveolar space occurs
through volume-regulated anion channels (VRACs), rather
than being a consequence of low-level cell lysis in response to
infection.
In this study, we show that RSV infection results in increased
release of both UTP and adenosine triphosphate (ATP) on Day 2,
and that systemic inhibition of de novo pyrimidine synthesis
with leflunomide, which reduces bronchoalveolar lavage (BAL)
nucleotide levels, reverses the impaired AFC, edema, hypo-
xemia, and diminution of nasal potential difference (NPD) in
RSV-infected mice, despite having no effect on RSV replication.
In contrast, systemic inhibition of de novo purine synthesis with
6-mercaptopurine (6-MP) has no detectable beneficial effects in
RSV-infected mice. Finally, we show that RSV-mediated inhibi-
tion of AFC on Day 2 can be prevented by pharmacologic block-
ade of VRAC-like channels. These studies confirm our prior
inference that UTP release is necessary for RSV-mediated inhi-
bition of AFC, and demonstrate that therapeutic inhibition of
the de novo pyrimidine synthesis and release pathway may allevi-
ate the symptoms of RSV infection. Our study is also the first
to successfully detect nucleotide release in the BAL fluid of
mice, and to demonstrate that such release is increased after
paramyxoviral infection of the respiratory tract. Some of the
results of these studies have been previously reported in the
form of abstracts (5, 6).
METHODS
Preparation of Viral Inocula and Infection of Mice
Preparation of viral stocks and intranasal infection of 8- to 12-wk-old
(20–25 g) pathogen-free BALB/c mice of either sex with RSV strain
A2 (106 plaque-forming units in 100 l) were performed (4). Data
for each experimental group were derived from a minimum of two
independent infections. All mouse procedures were approved by the
Institutional Animal Care and Use Committee of the University of
Alabama at Birmingham (Birmingham, AL).
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Mean Peripheral Blood Oxygen Saturation
Peripheral blood oxygen saturation was measured in conscious mice
(7), using a Preemie OxyTip sensor connected to a TuffSat pulse oxi-
meter (GE Medical Datex-Ohmeda, Inc., Madison, WI). Because of
the rapid pulse rate of mice, oximetry values are presented as mean
hemoglobin O2 saturation (SmO2) values from arterial and venous blood,
and thus appear low relative to true arterial saturation values.
NPD
The potential difference across the nares of anesthetized mice (with
the tail as reference) was recorded during perfusion of the nasal epithe-
lium with lactated Ringer’s solution (8). In some experiments, current
pulses of  60 nA were applied across the epithelium by a 12-V battery
in series with a 200-M resistor. Changes in NPD in response to the
current pulses (proportional to nasal transepithelial resistance, NRte)
were recorded (NPD).
BAL
BAL fluid was collected (4), using 1 ml of sterile normal saline for
cytokine ELISAs and cell counts, or 0.3 ml of sterile saline for nucleo-
tide assays. Lavagates were centrifuged to remove cells and superna-
tants were stored at –80C.
Nucleotide Measurement
Endogenous nucleotidases in BAL fluid were heat denatured (100C,
3 min) and UTP/ATP content was measured in uridine diphosphate–
glucose pyrophosphorylase and luciferin–luciferase assays, respectively (9).
Heme Measurement
BAL heme content was measured by Drabkin’s cyanmethemoglobin
assay (10).
Systemic Inhibition of De Novo Pyrimidine and
Purine Synthesis
Leflunomide (35 mg/kg per mouse in 300 l of distilled water con-
taining 1% methylcellulose) was administered to conscious mice once
daily by oral gavage for 8 d before infection, and then throughout the
infection period (11). Vehicle controls were gavaged with an equivalent
volume of 1% methylcellulose in distilled water. Uridine (1 g/kg in
100 l of 0.9% NaCl [11]) or an equal volume of saline was administered
to conscious mice by intraperitoneal injection every 12 h for 8 d before
infection, and then throughout the infection period. 6-MP (35 mg/kg
in 100 l of 1 N NaOH, adjusted to pH 7.9 with 2 M Na2HPO4 [12])
was administered by intraperitoneal injection every 24 h, for 5 d before
infection, and then throughout the infection period. All chemicals were
from Sigma (St. Louis, MO).
Serum Chemistry
Serum was analyzed with a VetScan chemistry system (Abaxis, Inc.,
Union City, CA), using the Comprehensive Diagnostic Profile reagent
rotor, in accordance with the manufacturer’s instructions.
Other Methods
All other methods were performed as previously described (4, 13, 14).
Statistical Analyses
Descriptive statistics were calculated with InStat software (GraphPad,
San Diego, CA). Differences between group means were analyzed by
analysis of variance or Student t test (paired for conscious SmO2 studies
only), with Tukey-Kramer multiple comparison post tests for analysis
of variance. All data values are presented as means  SEM.
RESULTS
Effect of RSV Infection and Leflunomide Treatment on BAL
Nucleotide Levels
Previously, we demonstrated that intranasal infection of BALB/c
mice with RSV results in a UTP-mediated decrease in AFC on
Day 2, but not on Day 6, despite continued viral replication (4).
In the current study, we found that BAL fluid from uninfected
or mock-infected mice contained equivalent levels of ATP and
UTP (Table 1). RSV infection resulted in a doubling of UTP
and ATP levels on Day 2, but no change in nucleotide levels
on Day 6, suggesting that the normalization of AFC on Day 6
results from a cessation of increased UTP release. Because lysis
of contaminating erythrocytes in BAL fluid samples (which might
be present at higher levels in infected mice as a result of lung
inflammation) could result in significant release of nucleotides
(particularly ATP), we measured BAL heme content. However,
the heme content of BAL fluid samples on Day 2 (7.3  1.4 M)
was not elevated compared with uninfected mice (7.3  0.7 M),
demonstrating that elevated BAL nucleotide levels after RSV
are not a consequence of contamination with lysed erythrocytes.
To directly confirm the causative relationship between in-
creased UTP release and reduced AFC, we treated mice with
leflunomide, an inhibitor of the de novo synthesis of pyrimidines.
Leflunomide treatment to Day 2 after infection reduced BAL
UTP and ATP content to levels below those in untreated, unin-
fected mice (Table 1). Uridine treatment, which stimulates py-
rimidine salvage, resulted in elevated BAL UTP, but not ATP,
on Day 2, whereas concomitant uridine and leflunomide treat-
ment significantly increased BAL nucleotide content over that
in untreated, RSV-infected mice, with a more pronounced effect
on UTP than ATP. Interestingly, leflunomide treatment of nor-
mal mice was also associated with elevated BAL UTP levels,
suggesting a possible compensatory activation of pyrimidine sal-
vage in response to the block in de novo pyrimidine synthesis.
Effect of Nucleotide Synthesis Inhibition on
Murine Metabolism
Leflunomide pretreatment was well tolerated by mice, and had
no effect on body weight before infection. Mild hepatomegaly
and mild, microvesicular, centrilobular hepatic fatty change was
observed on Day 2 (data not shown). However, similar fatty
change was also evident in liver tissue from methylcellulose-
treated mice, suggesting that it might be a consequence of stress
associated with repeated gavaging. Fatty change was somewhat
more severe in leflunomide-treated mice killed on Day 8. Leflu-
nomide therapy resulted in mild ( 50%) elevations of serum
alkaline phosphatase and amylase on Day 2 and Day 8, consistent
with mild liver dysfunction.
In contrast, 6-MP treatment to Day 2 appeared to be highly
toxic, resulting in severe weight loss, and some deaths, both
before and during the RSV infection period (overall mortality
TABLE 1. EFFECT OF RESPIRATORY SYNCYTIAL VIRUS
INFECTION AND LEFLUNOMIDE TREATMENT ON
BRONCHOALVEOLAR LAVAGE FLUID NUCLEOTIDE LEVELS
n* ATP† UTP†
Uninfected 11 16  2 16  4
Mock infected 6 13  4 10  4
Uninfected, leflunomide treated 8 54  9‡ 61  7‡
Day 2 14 38  7‡ 32  4§
Day 6 9 17  2 11  4
Day 2, leflunomide treated 9 6  1§ 5  2‡
Day 2, uridine treated 8 32  4§ 54  9§
Day 2, leflunomide and uridine treated 7 69  29 95  29§
Definition of abbreviations: ATP  adenosine triphosphate; UTP  uridine
triphosphate.
*Number of mice per group in which nucleotide levels were evaluated.
† Mean nucleotide concentration in bronchoalveolar lavage fluid  SEM (nmol/L).
‡ p  0.0005, compared with uninfected mice.
§ p  0.005, compared with uninfected mice.
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rate, 23%). Marked hepatomegaly and gross yellowing of liver
tissue were observed on Day 2 in 6-MP–treated mice, reflected
histologically by severe centrilobular fatty hepatic degeneration,
neutrophil infiltration, and formation of scattered areas of frank
coagulative necrosis, some involving entire liver lobules (data
not shown). 6-MP therapy resulted in hypoproteinemia, hypogly-
cemia, significant elevations of serum amylase (80%), and a
16-fold increase in serum alanine aminotransferase on Day 2,
indicative of severe hepatic degeneration. No other abnormali-
ties of serum chemistry were detected in mice treated with either
agent.
Effect of Nucleotide Synthesis Inhibition on RSV-mediated
Inhibition of AFC
In previous studies, we found that AFC was significantly de-
pressed (by 43% from mock-infected values) on Day 2, and that
the remaining AFC was amiloride insensitive (4). Leflunomide
pretreatment of RSV-infected mice blocked RSV-induced inhi-
bition of AFC on Day 2 (Table 2). This effect was not mimicked
by gavage with methylcellulose alone, and was reversed by con-
comitant uridine treatment. Uridine or saline vehicle treatment
alone had no effect on AFC in RSV-infected mice. Leflunomide
treatment also resulted in restoration of normal amiloride sensi-
tivity to AFC: amiloride reduced AFC by 57% in leflunomide-
treated mice on Day 2, and by 61% in uninfected mice, but had
no significant effect on the remaining AFC in untreated mice
on Day 2 (4). Finally, treatment of uninfected mice with leflu-
nomide or uridine also resulted in significant AFC inhibition.
This finding indicates that elevation of BAL nucleotides results
in impairment of AFC, irrespective of the underlying cause:
leflunomide therapy in normal mice or RSV infection for 2 d.
In contrast to the beneficial effect of leflunomide therapy,
but consistent with our previous observations that ATP degrada-
tion has no effect on AFC (4), a similar regimen of systemic
pretreatment with the de novo purine synthesis inhibitor 6-MP
had no stimulatory effect on AFC on Day 2 (Table 2).
Effect of Nucleotide Synthesis Inhibition on Lung
Water Content
Systemic therapy with leflunomide restored normal lung wet:dry
weight ratios on Day 2, whereas concomitant uridine treatment
TABLE 2. EFFECT OF NUCLEOTIDE SYNTHESIS INHIBITION
ON RESPIRATORY SYNCYTIAL VIRUS–MEDIATED
INHIBITION OF ALVEOLAR FLUID CLEARANCE ON DAY 2
n† AFC‡
Uninfected 7 34.89  2.49§
Uninfected  1.5 mM amiloride in instillate* 7 14.65  1.59||
Uninfected, leflunomide treated 17 29.98  1.5¶
Uninfected, uridine treated 8 18.18  2.67
Day 2* 25 22.01  1.04
Day 2  1.5 mM amiloride in instillate* 7 22.82  1.92
Day 2, methylcellulose treated 11 22.89  1.27
Day 2, leflunomide treated 14 34.52  2.1§
Day 2, leflunomide treated,  1.5 mM amiloride
in instillate 11 14.92  2.3||
Day 2, saline treated 10 19.55  1.4
Day 2, uridine treated 19 22.89  2.22
Day 2, leflunomide and uridine treated 10 21.9  2.69
Day 2, 6-mercaptopurine treated 11 16.52  2.51
Definition of abbreviation: AFC  alveolar fluid clearance.
*Dataset includes previously published data (4).
† Number of mice in which AFC was evaluated.
‡ Mean percentage of AFC  SEM.
§ p  0.0005, compared with AFC on Day 2.
|| p  0.0005, compared with AFC on Day 2  1.5 mM amiloride in instillate.
¶ p  0.005, compared with AFC on Day 2.
prevented this effect (Figure 1). However, systemic therapy with
6-MP, which had no beneficial effect on AFC on Day 2, did not
alter lung wet:dry weight ratios on Day 2. This finding further
strengthens the correlation between UTP release, impaired
AFC, and increased lung water content that we previously de-
scribed in RSV-infected mice (4).
Effect of RSV Infection and Leflunomide Treatment on
Lung Histopathology
Previously, we reported that RSV infection did not result in
epithelial cell death or sloughing of epithelium at any time (4).
Leflunomide treatment to Day 2 had no effect on pulmonary
pathology either on Day 2 or Day 8 (Figures 2a–2c). However,
continued leflunomide treatment to Day 8 did result in persis-
tence of both pronounced lymphoid infiltration around major
vessels, bronchi, and bronchioles, and parenchymal lymphoblast
infiltration (Figure 2d).
Effect of Nucleotide Synthesis Inhibition on BAL
Proinflammatory Cytokines
Leflunomide is used clinically as an immunosuppressive agent.
To verify the efficacy of our treatment regimen, we analyzed its
effect on BAL proinflammatory cytokines. Small amounts of
interleukin 1	 (IL-1	) and keratinocyte cytokine (KC) (the
murine homolog of human IL-8) were detected in BAL fluid
from mock-infected mice (Table 3). Significant amounts of IL-
1	, KC, and tumor necrosis factor 
 (TNF-
) were present in
BAL fluid on Day 2, but levels declined on Days 4 through 8.
IFN- was found in significant quantities in BAL fluid only on
Day 6 and Day 8. Neither IL-4 nor IL-10 was detectable at any
point in time (data not shown).
Leflunomide therapy significantly reduced levels of IFN-
,
IL-1	, KC, and TNF-
 in BAL fluid on Day 2 (Table 3). Concom-
itant uridine administration had no effect on BAL cytokines,
other than to increase IFN-
. 6-MP therapy resulted in a signifi-
cant decline in BAL IFN-
, IL-1	, KC, and TNF-
 levels compa-
rable to that caused by leflunomide therapy (Table 3), but as
noted above, had no effect on AFC.
Effect of Nucleotide Synthesis Inhibition on RSV Replication
in Mouse Lungs
Leflunomide has been shown to prevent replication of HIV-1
(15) and herpesviruses (16, 17) in vitro. Because our previous
Figure 1. Effect of nucleotide synthesis inhibition on lung water content
after respiratory syncytial virus (RSV) infection. Shown are the effects
of leflunomide, uridine, and 6-mercaptopurine (6-MP) treatment on
lung water content on Day 2 (n  7 or 8 for all groups, except n 
15 for 6-MP–treated mice). Lung water content was measured as the
wet:dry weight ratio. Black bar, mock; white bar, untreated; dark gray
bar, leflunomide; light gray bar, leflunomide  uridine; hatched bar,
6-MP. ***p  0.0005, compared with wet:dry weight ratio in uninfected
mice.
676 AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE VOL 173 2006
Figure 2. Effect of leflunomide
treatment on lung histopathol-
ogy after RSV infection. (a )
Day 2, leflunomide-treated
mice. (b ) Day 8, untreated
mice. (c ) Day 8, mice treated
with leflunomide to Day 2. (d )
Day 8, mice treated with leflu-





sections of formalin-fixed, par-
affin-embedded tissues (n  8/
group). Original magnifica-
tion, 40 for all images.
studies had demonstrated that the inhibitory effect of RSV on
AFC requires active viral replication (4), it was possible that
the beneficial effects of leflunomide might simply be a conse-
quence of inhibition of replication by this drug. However, RSV
replication on Day 2 was unaffected by leflunomide, uridine, or
6-MP treatment (Figure 3a).
Replication of RSV declines to undetectable levels on Day
8 (4, 18). Because this decline may be due to an influx of immune
cells into the lung (19), and because leflunomide, being an immu-
nosuppressive agent, might prevent this immune response, we
TABLE 3. EFFECT OF RESPIRATORY SYNCYTIAL VIRUS INFECTION AND NUCLEOTIDE SYNTHESIS
INHIBITION ON BRONCHOALVEOLAR LAVAGE FLUID PROINFLAMMATORY CYTOKINES
n§ IFN-
|| IFN-|| IL-1	|| KC|| TNF-
||
Mock 8 0¶ 0 10  6¶ 80  21¶ 0¶
Day 2 13 151  12 2  1 136  24 913  36 81  16
Day 4 8 ND 30  16 6  1¶ 106  27¶ 0¶
Day 6 8 ND 912  116¶ 20  3¶ 72  9¶ 1  1¶
Day 8 6 ND 195  25¶ 8  2¶ 88  16¶ 0¶
Day 2, LEF* 12 72  12¶ ND 20  8¶ 425  58¶ 0¶
Day 2, LEF  U† 10 246  68 ND 20  6¶ 334  62¶ 0¶
Day 2, 6-MP‡ 8 105  14** ND 9  3¶ 329  63¶ 0¶
Definition of abbreviations: 6-MP  6-mercaptopurine; KC  keratinocyte cytokine (murine homolog of human interleukin 8);
LEF  leflunomide; ND  not done; TNF-
  tumor necrosis factor 
; U  uridine.
* Leflunomide-treated mice.
† Leflunomide- and uridine-treated mice.
‡ 6-MP–treated mice.
§ Number of mice in which bronchoalveolar lavage (BAL) cytokine levels were measured.
|| Mean cytokine concentration in BAL fluid  SEM (pg/ml).
¶ p  0.0005, compared with cytokine concentration on Day 2.
** p  0.05, compared with cytokine concentration on Day 2.
evaluated RSV replication on Day 8 in mice treated with leflu-
nomide. When leflunomide treatment was continued throughout
the 8-d infection period, RSV replication persisted at high levels
on Day 8 (Figure 3b). However, when leflunomide treatment
was discontinued after Day 2, RSV replication was only mini-
mally increased on Day 8. A similar experiment using 6-MP
unfortunately proved impossible: treatment for such a prolonged
period resulted in extremely high mortality levels among the
mice (more than 90% by Day 6), and so had to be discontinued.
However, our findings with leflunomide support the notion that
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Figure 3. Effect of nucleotide synthesis inhibition on RSV replication in
mouse lungs. (a ) Effects of leflunomide, uridine, and 6-MP treatment
on virus replication on Day 2 (n  6 for untreated, uridine-treated, and
leflunomide- and uridine-treated mice; n  12 for leflunomide-treated
mice and 6-MP–treated mice). Black bar, untreated; white bar, leflunom-
ide; dark gray bar, uridine; light gray bar, leflunomide  uridine; hatched
bar, 6-MP. (b ) Effects of cessation of leflunomide treatment on Day 2
versus continued leflunomide treatment to Day 8 on virus replication on
Day 8 (n  6 for untreated mice; n 12 for mice treated with leflunomide to
Day 8; n  6 for mice treated with leflunomide to Day 2). Black bar,
untreated; white bar, leflunomide-treated to Day 2; gray bar, lefluno-
mide-treated to Day 8. Dashed lines indicate limits of detection of assay.
***p  0.0005, compared with Day 8 viral titer in untreated mice.
an intact inflammatory and immune response is essential to RSV
clearance from the lung.
Effect of Leflunomide Treatment on BAL and Peripheral
Blood Cell Counts
Infection with RSV for 8 d resulted in a significant increase in
BAL total cell count and mononuclear cells (alveolar macro-
phages and lymphocytes), compared with uninfected or mock-
infected mice (Figures 4a–4d). When leflunomide therapy was
continued to Day 8 after infection, BAL total cell, lymphocyte,
and neutrophil counts were significantly reduced, as compared
with untreated, infected mice, but peripheral blood lymphocyte
and neutrophil counts were elevated (data not shown). Interest-
ingly, when leflunomide treatment was discontinued on Day 2,
BAL total cell and neutrophil counts on Day 8 were normal,
although BAL lymphocyte counts remained low and peripheral
blood neutrophil counts remained elevated. Leflunomide treat-
ment had no effect on BAL macrophage or blood monocyte
counts at any time point, and treatment of normal mice resulted
in only mild lymphopenia and neutrophilia (data not shown).
Effect of RSV Infection and Leflunomide Treatment on
Peripheral Blood Oxygenation
Impairment of AFC on Day 2 was temporally associated with
a small but significant reduction in peripheral blood SmO2 in
conscious RSV-infected mice, compared with matched preinfec-
tion SmO2 values (Figure 5a). No decline in SmO2 was found at
other times after infection. Smee and coworkers (7) reported
SmO2 values (85%) for mock-infected mice similar to those re-
ported in the current study. Leflunomide therapy had no detri-
mental effect on preinfection SmO2 levels (data not shown) and
prevented the decline in matched SmO2 readings seen in un-
treated, RSV-infected, conscious mice on Day 2 (mean SmO2 on
Day 2, 84  1%; n  26).
We have shown previously that normal mice (with intact
AFC) are normoxic even at the end of the 30-min AFC period
(20). However, we found that the inability to clear alveolar fluid
normally on Day 2 after RSV infection was associated with
significant depression of SmO2 at the end of the 30-min AFC
period (Figure 5b). This depression in SmO2 was prevented by
leflunomide treatment, but was restored by concomitant uridine
treatment. To confirm these findings, we measured SmO2 in
uridine-treated, uninfected mice: the depressed AFC in these
animals was also associated with a significant and comparable
drop in SmO2 at the end of the AFC assay period. There was
no difference in duration of anesthesia for the AFC procedure
between any groups (data not shown). Taken together, these
findings support our hypothesis that defective AFC contributes
to development of hypoxemia in RSV disease.
Effects of RSV Infection and Leflunomide Treatment on NPD
NPD values in normal BALB/c mice in our study were compara-
ble to those previously reported for C57BL/6 mice (8, 21), and
were not altered by infection with RSV for 2 d. However, NPD
was significantly reduced on Day 4 and Day 8 (Figure 6a).
To estimate NRte after RSV infection, we measured the
change in NPD (NPD) elicited by applying a  60-nA pulse
to the nasal epithelium. NPD was significantly greater on Days
4 and 8 than in mock-infected controls (Figure 6b), indicating
that NRte increases after RSV infection, presumably as a result
of inhibition of active ion transport by the virus. NPD was also
significantly higher in normal mice after addition of 100 M
amiloride to the perfusate, indicating that an increase in NPD
truly reflects a reduction in current flow. Finally, treatment with
leflunomide throughout the infection period completely pre-
vented RSV-induced declines in NPD (Figure 6c) and NRte
(Figure 6d).
Effect of Anion Channel Blockade on RSV-mediated
Inhibition of AFC
VRAC-like channels have been proposed as candidates for nu-
cleotide release, and have been shown to mediate ATP release
from respiratory epithelial cells in vitro (22). Although no specific
VRAC inhibitors exist, these channels can be blocked by a vari-
ety of pharmacologic agents that, individually, have pleiotropic
effects on other cellular systems (reviewed in Nilius and cowork-
ers [23]). RSV-mediated inhibition of AFC on Day 2 was blocked
by addition to the AFC instillate of each of several structurally
unrelated VRAC inhibitors, but not by inhibitors of cystic fibro-
sis transmembrane regulator (24) or Ca2-activated Cl– channel
(25) activity (Table 4). Although studies using such nonspecific
inhibitors must be interpreted with due caution, the differential
blockade of RSV-mediated suppression of AFC by a broad spec-
trum of VRAC inhibitors provides strong evidence that VRAC
inhibition prevents the detrimental effects of RSV on AFC.
Addition of 500 nM UTP to the AFC instillate completely
reversed the effect of VRAC inhibition (Table 4), indicating
that reduced AFC in RSV infection is not a consequence of
increased Cl– secretion through VRACs (if it were, UTP would
have no effect on AFC in the presence of a VRAC inhibitor)
but is instead a result of UTP release through these channels.
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Figure 4. Effect of leflunomide treatment on bron-
choalveolar lavage (BAL) cell counts on Day 8 after
RSV infection. (a ) Total cell counts. (b ) Alveolar
macrophage counts. (c ) Lymphocyte counts. (d )
Neutrophil counts. (n  9 for uninfected mice and
for untreated, RSV-infected mice; n  6 for mice
treated with leflunomide to Day 2 or to Day 8).
Black bars, uninfected; white bars, untreated; dark-
gray bars, leflunomide to Day 2; light-gray bars,
leflunomide to Day 8. *p  0.05, **p  0.005,
***p  0.0005, compared with untreated, RSV-
infected mice on Day 8.
DISCUSSION
Previously, we demonstrated that RSV, but not mock infection,
inhibits AFC in BALB/c mice, and inferred that inhibition of
AFC by RSV is mediated by UTP, released into the airspace
lining fluid and acting in a paracrine fashion on epithelial P2YRs
to inhibit active Na transport (4). Subsequently, we have been
able to perform the technically challenging task of measuring
nucleotide triphosphate levels in mouse BAL fluid samples,
which has not previously been reported. This has allowed us to
confirm the temporal and functional association between ele-
vated BAL nucleotide levels and impaired AFC.
Effect of RSV Infection and Leflunomide Treatment on
BAL Nucleotides
Levels of ATP and UTP in BAL fluid from normal mice appear
to be extremely low (10–15 nM). However, BAL fluid samples
are by their nature diluted and local nucleotide concentrations
at the epithelial surface may be considerably higher. There is
also growing evidence that within the airspace lining fluid, a
network of ectonucleotidases and ectonucleoside diphosphoki-
nases may catalyze breakdown and interconversion of released
nucleotides to locally modulate P2YR ligand profiles (reviewed
in Reference 26). Indeed, previous studies have shown that nu-
cleotide measurements may underestimate true nucleotide levels
by up to 10-fold, because almost 90% of ATP is rapidly hy-
drolyzed on release from cells (27, 28). Donaldson and coworkers
(29) reported steady state UTP concentrations in normal human
nasal aspirates to be about 40 nM, although they found signifi-
cantly higher ATP levels (470 nM). It is unclear whether this
discrepancy reflects differences in sampling site, species, sam-
pling technique, or dilution factor.
Infection with RSV results in only a 20 nM increase in UTP
release on Day 2, but this is sufficient to inhibit AFC by more
than 40%. This finding supports our previous inference that UTP
levels are elevated after RSV infection, but that this elevation
need not be large (4). Surprisingly, given that our previous stud-
ies had shown that RSV-mediated inhibition of AFC was a
consequence of P2YR activation, but not by ATP (4), RSV
infection increased BAL ATP levels. Our findings are consistent
with a previous study by Lazarowski and coworkers (30), which
demonstrated parallel release of UTP and ATP from human
astrocytoma cells in response to mechanical stimulation. Mouse
lung expresses at least two subtypes of P2YR: P2Y2R and P2Y6R
(31). Because ATP and UTP are equivalent ligands for P2Y2R,
the inhibitory effect of UTP on AFC in RSV infection may
instead be mediated by the UTP metabolite UDP, acting via
P2Y6R, for which it is the sole ligand. Unfortunately, no subtype-
specific P2YR antagonists currently exist.
Given the normal respiratory epithelial intracellular ATP
level ( 20 nmol/106 cells [22]), a 20 nM increase in ATP content
in 300 l of BAL fluid is equivalent to the ATP content of only
300 cells, and so could result from a low level of viral cytopathi-
city that is undetectable histologically. Even if, as in T cells (32),
intracellular UTP levels are 10-fold lower, a similar increase in
BAL UTP content would require lysis of only 3,000 cells. How-
ever, the blocking effect of VRAC inhibitors on RSV-mediated
AFC inhibition indicates that BAL nucleotide levels are elevated
because of increased release from cells, rather than cell lysis.
Moreover, lysed cells are unlikely to be a significant source of
BAL nucleotides, because BAL nucleotide levels are increased
on Day 2, when no lactate dehydrogenase is detectable in BAL
fluid (4), but are not increased on Day 6, when BAL lactate
dehydrogenase levels are elevated.
It remains unclear why RSV replication triggers UTP release
on Day 2, but not on Day 6, but this difference may reflect
temporal variations in either viral gene product expression or
cell tropism. Alternatively, cessation of UTP release may be
secondary to the onset of immune-mediated viral clearance from
the lungs, and a concomitant alteration in the cytokine milieu.
However, although nucleotides can modulate cytokine release
by inflammatory cells (reviewed in Reference 33), there is no
evidence that cytokines can modulate nucleotide release (26).
Nevertheless, there is a clear temporal association in our studies
between elevated BAL nucleotide levels and impaired AFC
after RSV infection. An in vitro study demonstrated that another
paramyxovirus, Sendai virus, also inhibits active Na transport
Davis, Lazarowski, Hickman-Davis, et al.: Leflunomide Therapy in RSV Disease 679
Figure 5. Effect of RSV infection and leflunomide treatment on periph-
eral oxygenation. (a ) Time course of effect of RSV infection on SmO2 in
conscious BALB/c mice (n  10–36/d, paired data). *p  0.05, com-
pared with preinfection values. (b ) Effect of leflunomide and uridine
treatment on peripheral SmO2 in anesthetized, uninfected mice, or on
mice infected with RSV for 2 d, at the conclusion of the 30-min AFC
assay (n  8 or 9/group). Black bars, untreated, hatched bar, uridine;
gray bar, leflunomide; white bar, leflunomide  uridine. **p  0.005,
***p  0.005, compared with uninfected, untreated mice.
and stimulates Cl– secretion by an ATP/P2YR-mediated mecha-
nism (34). However, nucleotide release was not formally demon-
strated, and the kinetics of the effect differ significantly from
our studies.
Inhibition of de novo pyrimidine synthesis with leflunomide
had a suppressive effect on BAL UTP and ATP levels. De novo
purine and pyrimidine synthesis pathways are usually concor-
dantly regulated (reviewed in Reference 35), and these findings
are consistent with that observation. Uridine treatment not only
reversed the decrease in BAL UTP and ATP levels induced by
leflunomide therapy during RSV infection, but also resulted in
a significant increase in both UTP and ATP levels above those
in infected, untreated mice. Interestingly, BAL nucleotide levels
were also elevated in leflunomide-treated normal mice, sug-
gesting that inhibition of de novo UTP synthesis normally results
in a compensatory increase in salvage pathway synthesis. Taken
together, these data indicate that UTP release is limited by UTP
availability in cells: the pool of UTP that is normally available
for release may be small, and is primarily derived from de novo
pyrimidine synthesis, but UTP release can be significantly in-
creased by exogenous or compensatory activation of the pyrimi-
dine salvage pathway. However, it appears that actively replicat-
ing RSV depletes the free nucleotide pool, so that salvage
pathway activity can no longer compensate for the inhibitory
effects of leflunomide on de novo pyrimidine synthesis, and UTP
release into the BAL fluid therefore effectively ceases.
Effect of De Novo Nucleotide Synthesis Inhibition on AFC
To directly confirm the causative relationship between increased
nucleotide release and reduced AFC, we treated mice with inhib-
itors of de novo synthesis of pyrimidines (leflunomide, which
inhibits dihydroorotate dehydrogenase [36]) or purines (6-MP,
which inhibits inosine monophosphate dehydrogenase). Leflu-
nomide has additional nonspecific inhibitory effects on tyrosine
kinases, but these are not reversible on administration of exoge-
nous uridine, which allows pyrimidine synthesis via a salvage
pathway, bypassing the leflunomide block. To our knowledge,
leflunomide and 6-MP have previously been used in mice solely
as immunosuppressive agents; this is the first occasion on which
they have been used to directly modulate epithelial cell function.
Despite differential toxicities, both agents produced a similar
degree of immune suppression in RSV-infected mice, as assessed
by BAL proinflammatory cytokine and immune cell levels, con-
firming that therapy with both agents was successfully adminis-
tered. However, unlike leflunomide, 6-MP had no beneficial
effect on AFC on Day 2. Finally, treatment of uninfected mice
with leflunomide also resulted in inhibition of AFC. However,
whereas BAL nucleotide levels in uninfected, leflunomide-
treated mice were comparable to, or slightly higher than, levels
in untreated, RSV-infected mice on Day 2, the degree of AFC
inhibition was significantly less. This finding suggests that, unlike
in RSV-infected mice, AFC in normal mice may be regulated
by multiple factors.
The finding that 6-MP induces a degree of immunosuppres-
sion comparable to that of leflunomide, but has no effect on AFC,
argues that the beneficial effects of leflunomide pretreatment on
AFC in RSV infection are independent of its immunosuppressive
effects. Indeed, even without considering the absence of effect
of 6-MP on AFC, there is little evidence that the decline in AFC
on Day 2 is a consequence of the immune response to the virus.
Although certain proinflammatory cytokines have been shown
to modulate Na transport in vitro or in vivo (37–40), analysis
of BAL fluid from RSV-infected mice reveals no temporal corre-
lation between pulmonary inflammation and inhibition of AFC.
For example, whereas IFN- has been shown to inhibit Na
transport in vitro (38), no IFN- is detectable in BAL fluid on
Day 2, when AFC is most depressed, and AFC values are normal
on Day 6, when BAL IFN- levels are highest. Moreover, the
effects of leflunomide on RSV-induced AFC inhibition, in-
creased lung water content, and increased BAL UTP levels are
all reversed by uridine, but, with the exception of IFN-
, its
effects on BAL proinflammatory cytokines are not. Thus, the
beneficial effect of leflunomide on AFC results from its inhibi-
tory effect on de novo pyrimidine synthesis, whereas its immuno-
suppressive effect results chiefly from nonspecific inhibition of
tyrosine kinases, which is consistent with previous studies (11,
41). IFN-
 cannot be the mediator of impaired AFC, because
BAL IFN-
 is reduced in 6-MP–treated mice, despite persistence
of impaired AFC on Day 2 in these animals.
Our previous studies had demonstrated that the inhibitory
effect of RSV on AFC requires active viral replication (4), and
the beneficial effect of leflunomide on AFC on Day 2 might
therefore simply be a consequence of inhibition of RSV replica-
tion. This is clearly not the case; if anything, leflunomide treat-
ment tends to prolong viral replication in mouse lungs. Neverthe-
less, prolonged viral replication on Day 8 was curtailed if
leflunomide treatment was discontinued on Day 2, despite clear
suppression of BAL lymphocyte responses, suggesting that com-
ponents of the innate immune response may play a significant
role in viral clearance. Our histopathologic and cell count find-
ings support such a role: continuation of leflunomide treatment
to Day 8 after infection resulted in an apparent impairment in
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Figure 6. Effect of RSV infection and leflunom-
ide treatment on nasal potential difference
(NPD) in BALB/c mice. (a ) Effect of RSV infection
on NPD. M (black bar)  mock-infected mice;
white bar, RSV-infected mice. (b ) Effect of
amiloride or RSV infection on change in NPD
(NPD) after application of  60-nA pulses to
nasal epithelium. M (black bar)  mock-infected
mice; M  A (white bar)  mock-infected mice,
100 M amiloride in perfusate; 4, 8  days after
RSV infection (shading added for emphasis).
(c ) Effect of leflunomide treatment on NPD in
RSV-infected mice. Black bar, vehicle; white bars,
leflunomide. (d ) Effect of leflunomide treat-
ment on NPD on Day 4 after RSV infection.
Black bars, untreated; white bars, leflunomide.
*p  0.05, **p  0.005, compared with mock-
infected animals on Day 4, ***p  0.0005.
n  5–9 for all groups.
leukocyte recruitment to the airspaces (trapping of leukocytes
around major blood vessels, with reduced BAL and elevated
peripheral blood leukocyte counts), whereas cessation of leflu-
nomide treatment on Day 2 resulted only in a reduction in BAL
neutrophil levels and peripheral blood lymphocytosis. However,
the mechanism underlying impaired leukocyte recruitment is
currently unknown. Finally, and despite having a mechanism of
action similar to that of ribavirin (both are inhibitors of inosine
monophosphate dehydrogenase), 6-MP treatment also has no
inhibitory effect on RSV replication.
TABLE 4. EFFECT OF ANION CHANNEL INHIBITORS ON
RESPIRATORY SYNCYTIAL VIRUS–MEDIATED INHIBITION OF
ALVEOLAR FLUID CLEARANCE ON DAY 2
Inhibitor Target Concentration (M) n† AFC‡
None* — — 25 22.01  1.04
Fluoxetine VRAC 10 16 34.54  0.79§
Fluoxetine  UTP VRAC 10/0.5 8 23.64  2.42
Tamoxifen VRAC 25 9 34.50  0.94§
Clomiphene VRAC 20 8 31.05  2.65§
Verapamil VRAC 10 6 33.04  1.49||
NPPB VRAC 100 9 32.70  2.18||
R()-IAA 94 VRAC 100 5 34.25  1.98§
Glibenclamide CFTR 100 9 24.24  4.24
Niflumic acid CaCC 100 10 20.28  1.53
Definition of abbreviations: AFC  alveolar fluid clearance; CaCC  Ca2-
activated Cl channel; CFTR  cystic fibrosis transmembrane regulator; NPPB 
5-nitro-2-(3-phenylpropylamino) benzoic acid; R()-IAA 94  R()-([6,7-dichl-
oro-2-cyclopentyl-2,3-dihydro-2-methyl-1-oxo-1H-inden-5-yl]-oxy) acetic acid
94; UTP  uridine triphosphate; VRAC  volume-regulated anion channel.
*Dataset includes previously published data (4).
† Number of mice in which AFC was evaluated.
‡ Mean percentage of AFC  SEM.
§ p  0.0005, compared with AFC on Day 2
|| p  0.005, compared with AFC on Day 2.
Effect of Leflunomide on Hypoxemia in RSV Infection
Hypoxemia is a primary indicator of disease in children with
RSV (42). We previously hypothesized that hypoxemia could
result from impaired AFC in RSV infection (4), and in this
study we found that infection of mice with RSV resulted in mild
hypoxemia in conscious mice on Day 2, when compared with
matched preinfection SmO2 values. Although the reduction in
SmO2 at this time point was small (3%), this may in reality reflect
a significant reduction in arterial Po2. Indeed, a comparable
decline in SmO2 was reported in BALB/c mice infected with
vaccinia virus on Day 5, just before the onset of mortality (7).
Because RSV induces only mild pulmonary disease in the mouse,
a greater change in SmO2 would have been surprising. Moreover,
when infected mice were subjected to AFC studies and the
resultant stress of additional fluid loading of the lungs, their
impaired AFC capacity did lead to development of severe hypo-
xemia. Both the hypoxemia observed in conscious mice and that
seen at the end of the AFC procedure could be prevented by
leflunomide administration, suggesting that RSV-induced hypo-
xemia and pulmonary edema may be at least partially the result
of impaired AFC. Although no decline in SmO2 was observed
on Day 4, this may be a consequence of both the inherent vari-
ability and insensitivity in SmO2 measurements in conscious mice,
and the relatively reduced level of hypoxemia that might be
predicted to result from a smaller impairment of AFC at this
time point.
Effect of Leflunomide on NPD in RSV-infected Mice
We found that NPD was essentially absent in RSV-infected mice
on Day 4 and Day 8, but was normal on Day 2 when AFC was
most impaired. The reason for this discrepancy in timing of ion
transport abnormalities between the upper and lower respiratory
tract is unclear, but may reflect differences in kinetics of viral
replication between the two sites. Nevertheless, our finding of
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altered NPD in response to RSV infection is consistent with
previous studies. NPD values are abnormally low in normal
adult volunteers after nasal instillation of rhinovirus (43), and
in children with cystic fibrosis who have rhinitis (44, 45). These
reductions in NPD were assumed to be a consequence of nonspe-
cific inflammation of the nasal mucosa, resulting in a leaky epi-
thelium and dissipation of the normal potential gradient via
paracellular pathways (46, 47). However, our data indicate that
NRte does not decrease after RSV infection, indicating that re-
ductions in NPD are a result of reduced Na conductance across
the nasal epithelium. Again, leflunomide treatment prevents the
dysregulation of NPD and NRte seen in untreated, RSV-infected
mice, demonstrating that the beneficial effects of systemic leflu-
nomide therapy extend throughout the respiratory tract.
RSV Triggers Nucleotide Release via VRACs
Several pathways have been proposed for nucleotide release
from cells: exit via nucleotide or VRAC-like channels, facilitated
diffusion, and exocytosis of nucleotide-filled granules (reviewed
in Reference 48). We found that the inhibitory effects of RSV
on AFC on Day 2 could be prevented by the addition of VRAC
inhibitors to the AFC instillate, but not by blockers of other
anion channels. We should note, however, that our findings pro-
vide no information regarding nucleotide release pathways in
uninfected lung, and demonstrate only that VRACs are the
pathway of nucleotide release during RSV infection. Moreover,
we cannot exclude the possibility that, rather than being the
release pathway, VRACs merely facilitate nucleotide release
via another mechanism, or modulate UTP levels by altering
synthesis or degradation mechanisms.
Conclusions
Taken together, our data suggest that activation of the UTP
VRAC release pathway may be a component of an epithelial
paracrine signaling system that is activated by RSV infection.
In this model, release of UTP (and perhaps ATP) in response
to RSV infection may be viewed as a double-edged sword for
the host, resulting in impairment of AFC and perhaps hypo-
xemia, but also aiding clearance of the virus from the lung, by
promoting surfactant release and mucociliary clearance (26).
Indeed, Huang and coworkers (49) have proposed that local
physical stimulation of airway surfaces, by activating apical nu-
cleotide release and P2YR signaling, may trigger mechanisms
that flush noxious stimuli away. We propose that viral infections
promote a similar response. Moreover, UTP, by its effects on
P2YR on immune cells (50, 51), may also stimulate the proin-
flammatory cytokine cascade that initiates viral clearance from
the lungs. However, this inflammatory process may itself be
responsible for lung injury: several studies have demonstrated
that depletion of T cells leads to markedly attenuated illness
and pulmonary pathology, despite viral persistence in the lungs
for up to 4 wk after infection (52, 53).
In conclusion, our studies indicate that RSV infection results
in increased nucleotide release into the airspace lining fluid, and
that these nucleotides, by impairing AFC, ultimately engender
significant physiologic impairment of the host. Moreover, we
show that systemic or local therapy with inhibitors of dihydrooro-
tate dehydrogenase or UTP release may be of therapeutic benefit
in RSV disease, by promoting normal AFC and thereby helping
to counter the development of hypoxemia. Although impaired
AFC has been described after a variety of physical insults to the
lung (reviewed in Reference 1), previous attempts to reverse
such defects in AFC have focused on the use of 	-adrenergic
agonists to restore normal AFC (54). To our knowledge, we are
the first to successfully apply an entirely different approach—
that is, to directly block the mediator responsible for impaired
AFC in the injured lung.
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